Country: Ավստրալիա
language: անգլերեն
source: Department of Health (Therapeutic Goods Administration)
atropine sulfate monohydrate, Quantity: 1.2 mg/mL
Bridgewest Perth Pharma Pty Ltd
Injection, solution
Excipient Ingredients: water for injections; sodium chloride
Intravenous, Subcutaneous, Intramuscular
1mL x 50
(S4) Prescription Only Medicine
INDICATIONS AS AT 23 OCTOBER 2001: Preanaesthetic medication to reduce salivary secretions and bronchial secretions. To prevent cholinergic cardiac effects such as cardiac arrhythmias, hypotension and bradycardia. Management of patients with acute myocardial infarction and sinus bradycardia who have associated hypotension and increased ventricular irritability. Concurrent administration with anticholinesterase agents (eg. neostigmine, physostigmine) to block the adverse muscarinic effects of these agents following surgery to terminate curarisation. For poisoning by organophosphate pesticides, atropine may be used concomitantly with a cholinesterase reactivator such as pralidoxime to reverse muscarinic effects.
Visual Identification: Clear, colourless solution; Container Type: Ampoule; Container Material: LDPE; Container Life Time: 18 Months; Container Temperature: Store below 25 degrees Celsius
Registered
1991-08-13
ATROPINE INJECTION BP _(Atropine sulfate monohydrate )_ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Atropine Injection. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have benefits and risks. Your doctor has weighed the risks of you taking Atropine Injection against the benefits this medicine is expected to have for you. This medicine is likely to be used while you are at the clinic or in hospital. If possible, please read this leaflet carefully before this medicine is given to you. In some cases this leaflet may be given to you after the medicine has been used. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET. You may need to read it again. WHAT ATROPINE INJECTION IS USED FOR Atropine sulfate monohydrate belongs to a group of medicines called antimuscarinic agents. Atropine Injection is given before anaesthesia to decrease mucus secretions, such as saliva. During anaesthesia and surgery, atropine is used to help keep the heart beat normal. Atropine sulfate monohydrate is also used to block or reverse the adverse effects caused by some medicines and certain type of pesticides. Atropine Injection may be used for the management of other conditions that are not mentioned above. Your doctor will be able to tell you about the specific condition for which you have been prescribed Atropine Injection. This medicine is available only with a doctor's prescription. BEFORE YOU ARE GIVEN ATROPINE INJECTION _WHEN YOU MUST NOT BE GIVEN_ _IT_ DO NOT USE ATROPINE INJECTION IF YOU HAVE AN ALLERGY OR HAVE HAD AN UNUSUAL REACTION TO ATROPINE OR ANY OF THE ANTICHOLINERGIC MEDICINES SUCH AS HYOSCYAMINE AND BELLADONNA. DO NOT USE ATROPINE INJECTION IF YOU HAVE OR HAVE HAD ANY MEDICAL CONDITIONS, ESPECIALLY THE FOLLOWING: • severe and chronic inflammation of the large intestine and rectum • gastrointestinal blockage and/or diseases • en read_full_document
Version : pfpatroi11021 Supersedes: pfpatroi10919 Page 1 of 12 AUSTRALIAN PRODUCT INFORMATION – ATROPINE INJECTION BP (ATROPINE SULFATE MONONHYDRATE) 1. NAME OF THE MEDICINE Atropine sulfate monohydrate 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Atropine Injection BP is a sterile, isotonic, preservative free solution containing 600 microgram of atropine sulfate monohydrate in 1mL or 1.2 mg of atropine sulfate monohydrate in 1 mL. 3. PHARMACEUTICAL FORM Solution for injection 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS • Preanaesthetic medication to reduce salivary secretions and bronchial secretions • to prevent cholinergic cardiac effects such as cardiac arrhythmias, hypotension and bradycardia • management of patients with acute myocardial infarction and sinus bradycardia who have associated hypotension and increased ventricular irritability • concurrent administration with anticholinesterase agents (e.g. neostigmine, physostigmine) to block the adverse muscarinic effects of these agents following surgery to terminate curarisation • for poisoning by organophosphate pesticides, atropine may be used concomitantly with a cholinesterase reactivator such as pralidoxime to reverse muscarinic effects. 4.2 DOSE AND METHOD OF ADMINISTRATION Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer unless solution is clear and seal is intact. Atropine Injection may be given by subcutaneous (SC), intramuscular (IM) or direct intravenous (IV) injection. Atropine Injection should not be added to any IV infusion solutions for administration. Atropine Injection contains no microbial agent. It should be used in one patient on one occasion only and any residue discarded. Version : pfpatroi11021 Supersedes: pfpatroi10919 Page 2 of 12 CARDIOPULMONARY RESUSCITATION The usual adult dose is 0.4 – 1 mg IV, which may be repeated at 5 minute intervals until the desired heart rate is achieved. Th read_full_document